New options of pharmacological treatment of osteoporosis Edward Czerwiński Ortop Traumatol Rehabil 2006; 8(4):367-371 ICID: 465261
Article type: Review article
IC™ Value: 5.37
Abstract provided by Publisher
Currently a wide range of drugs efficient in osteoporotic fractures are on disposal. Bisfosphonates are the most important group, which are currently administered in a weekly dosage: Alendronate dose 70mg and Risedronate – 35mg. Since few months a therapy once a month with Ibandronate 150mg is also available. Apart from antyresorptive therapy there are also other groups of medications. Strontium Ranelate not only decreases bone resorption but also increases bone formation. Parathyroid hormone subcutaneous strongly promotes bone formation. Denosumab given subcutaneous once in half a year elevates bone mineral density. Hormone Replacement Therapy is not applied in prevention of osteoporotic fracture, however, it is still in use in treatment of disorders of menopause. In countries with correct health policy the doctors have complete possibility to adjust appropriate medications according to the patient's health state.
ICID 465261 PMID 17597679 - click here to show this article in PubMed